Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases

Clinical Reviews in Allergy and Immunology

Volumn 44, Issue 1, 2013, Pages 84-97

  Roux Lombard, P ^a   Pagano, S ^a   Montecucco, F ^b   Satta, N ^a   Vuilleumier, N ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Atherosclerosis; Auto antibodies; Cardiovascular disease; Humoral autoimmunity; Risk stratification

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 ANTIBODY; AUTOANTIBODY; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN ANTIBODY; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN ANTIBODY; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; HEART RATE; HUMAN; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION;

ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTORS;

EID: 84872688697     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8233-z     Document Type: Article

References (144)

1. Eyre H, Kahn R, Robertson RM et al (2004) Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 109(25):3244-3255
2. Yan ZQ, Hansson GK (2007) Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 219:187-203 (Pubitemid 47390007)
3. Packard RR, Libby P (2008) Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54(1):24-38 (Pubitemid 351182593)
4. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6(7):508-519 (Pubitemid 43980523)
5. Binder CJ, Chang MK, Shaw PX et al (2002) Innate and acquired immunity in atherogenesis. Nat Med 8(11):1218-1226 (Pubitemid 35373552)
6. Hansson GK, Nilsson J (2008) Introduction: atherosclerosis as inflammation: a controversial concept becomes accepted. J Intern Med 263(5):462-463 (Pubitemid 351533559)
7. Pereira IA, Borba EF (2008) The role of Inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly 138(37-38):534-539
8. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340(2):115-126 (Pubitemid 29054847)
9. Schwartz SM, Galis ZS, Rosenfeld ME, Falk E (2007) Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol 27(4):705-713 (Pubitemid 46606695)
10. Johnson JL, George SJ, Newby AC, Jackson CL (2005) Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 102(43):15575-15580 (Pubitemid 41528098)
11. Samnegard A, Silveira A, Tornvall P, Hamsten A, Ericsson CG, Eriksson P (2006) Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 259(5):530-536
12. Samnegard A, Silveira A, Lundman P et al (2005) Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 258(5):411-419 (Pubitemid 41546556)
13. Steffel J, Lüscher TF, Tanner FC (2006) Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113(5):722-731
14. Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145(5):408-415 (Pubitemid 27084212)
15. Haque S, Mirjafari H, Bruce IN (2008) Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol 19(4):338-343
16. Salmon JE, Roman MJ (2008) Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 121(10 Suppl 1):S3-S8
17. Marai I, Shechter M, Langevitz P et al (2008) Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease. Am J Cardiol 101(8):1094-1097
18. Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827-1832 (Pubitemid 36237580)
19. Iverson GM, Matsuura E, Victoria EJ, Cockerill KA, Linnik MD (2002) The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI auto-antibodies by ELISA. J Autoimmun 18(4):289-297 (Pubitemid 34970053)
20. Matsuura E, Kobayashi K, Matsunami Y et al (2009) Autoimmunity, infectious immunity, and atherosclerosis. J Clin Immunol 29:714-721
21. Greco TP, Conti-Kelly AM, Greco T Jr et al (2009) Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol 132(4):613-620
22. Meroni PL, Peyvandi F, Foco L et al (2007) Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 5(12):2421-2428 (Pubitemid 350154352)
23. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 8(11):998-1005
24. Brey RL, Stallworth CL, McGlasson DL et al (2002) Antiphospholipid antibodies and stroke in young women. Stroke 33(10):2396-2400
25. Tuhrim S, Rand JH, Wu XX et al (1999) Elevated anticardiolipin antibody titer is a strong risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 30:1561-1565 (Pubitemid 29379603)
26. Vaarala O, Manttari M, Manninen V et al (1995) Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91:23-27
27. Zuckerman E, Toubi E, Shiran A et al (1996) Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study. Am J Med 171:381-386 (Pubitemid 26392855)
28. Levine SR, Salowich-Palm L, Sawaya KL et al (1997) IgG anticardiolipin antibody titer and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28:1660-1666
29. Tsutsumi A, Matsuura E, Ichikawa K et al (1996) Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 39:1466-1474 (Pubitemid 26314979)
30. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA (2009) Anti-β2- glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. J Clin Immunol 29:714-721
31. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH (2007) Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 109(4):1490-1494 (Pubitemid 46239580)
32. de Laat B, Pengo V, Pabinger I, Musial J et al (2009) The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7(11):1767-1773
33. Iverson GM, von Mühlen CA, Staub HL, Lassen AJ, Binder W, Norman GL (2006) Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA auto-antibodies that preferentially target domain four of beta2-GPI. J Autoimmun 27(4):266-271 (Pubitemid 46199123)
34. Ranzolin A, Bohn JM, Norman GL et al (2004) Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol 83(2):137-144 (Pubitemid 39159272)
35. Veres K, Lakos G, Kerenyi A et al (2004) Antiphospholipid antibodies in acute coronary syndrome. Lupus 13(6):423-427 (Pubitemid 38931773)
36. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katsier E (1999) Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 96:5164-5168 (Pubitemid 29214553)
37. Koike T, Ichikawa K, Atsumi H, Kasahara T, Matsuura E (2000) B2-glycoprotein I anti-B2-glycoprotein I interactions. J Autoimmun 15:97-100
38. Yang CD, Chen SL, Shen N et al (1997) The fifth domain of B2-glycoprotein I contains antigenic epitopes recognized by anticardiolipin antibodies derived from patients with the antiphospholipid syndrome. APLAR J Rheumatol 1:96-100
39. Greco TP, Conti-Kelly AM, Anthony JR et al (2010) Oxidized-LDL/beta(2)- glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes. Am J Clin Pathol 133(5):737-743
40. de Groot PG, Derksen RH, de Laat B (2008) Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost 34(4):347-355
41. Favaloro EJ, Wong RC (2008) Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 34(4):389-410
42. Devreese K, Hoylaerts MF (2010) Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem 56(6):930-940
43. Cugno M, Borghi MO, Lonati LM et al (2010) Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 34(2):105-110
44. Simoncini S, Sapet C, Camoin-Jau L et al (2005) Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 17(4):489-500 (Pubitemid 40568124)
45. Alves JD, Clapp BR, Stidwill R et al (2006) Human monoclonal IgG anticardiolipin antibodies induce nitric oxide synthase expression. Atherosclerosis 185(2):246-253
46. Sitia S, Tomasoni L, Atzeni F et al (2010) From endothelial dysfunction to atherosclerosis. Autoimmun Rev 9(12):830-834
47. Raschi E, Borghi MO, Grossi C, Broggini V, Pierangeli S, Meroni PL (2008) Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 17(10):937-942
48. Satta N, Dunoyer-Geindre S, Reber G et al (2007) The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 109(4):1507-1514 (Pubitemid 46239583)
49. Dunoyer-Geindre S, Kwak BR, Pelli G et al (2007) Immunization of LDL receptor-deficient mice with beta2-glycoprotein one or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques. Thromb Haemost 97(1):129-138 (Pubitemid 46242394)
50. Cederholm A, Svenungsson E, Jensen-Urstad K et al (2005) Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 25(1):198-203 (Pubitemid 40054276)
51. Rand JH, Wu XX, Quinn AS, Taatjes DJ (2008) Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 17(10):922-930
52. Frostegård AG, Su J, von Landenberg P, Frostegård J (2010) Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease. Scand J Rheumatol 39(1):77-83
53. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T (1997) Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107:569-573 (Pubitemid 27102148)
54. Kobayashi K, Matsuura E, Liu Q et al (2001) A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42:697-709 (Pubitemid 32507169)
55. Kuwana M, Matsuura E, Kobayashi K et al (2005) Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 105:1552-1557 (Pubitemid 40223674)
56. Yamaguchi Y, Seta N, Kaburaki J, Kobayashi K, Matsuura E, Kuwana M (2007) Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome. Blood 110:4312-4318 (Pubitemid 351377796)
57. Kajiwara T, Yasuda T, Matsuura E (2007) Intracellular trafficking of β2- glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun 29:164-173 (Pubitemid 47385117)
58. Hartl FU, Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295:1852-1858 (Pubitemid 34214115)
59. Xu Q (2002) Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 22:1547-1559
60. Berberian PA, Myers W, Tytell M, Challa V, Bond MG (1990) Immunohistochemical localization of heat shock protein-70 in normal-appearing and atherosclerotic specimens of human arteries. Am J Pathol 136:71-80 (Pubitemid 20034954)
61. Johnson AD, Berberian PA, Tytell M, Bond MG (1995) Differential distribution of 70-kD heat shock protein in atherosclerosis: its potential role in arterial SMC survival. Arterioscler Thromb Vasc Biol 15:27-36
62. Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, Wick G (1993) Immunology of atherosclerosis: demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 142:1927-1937 (Pubitemid 24057087)
63. Xu Q, Willeit J, Marosi M et al (1993) Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341:255-259 (Pubitemid 23038021)
64. Xu Q, Kiechl S, Mayr M et al (1999) Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 100:1169-1174 (Pubitemid 29426591)
65. Burian K, Kis Z, Virok D et al (2001) Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis. Circulation 103:1503-1508 (Pubitemid 32226256)
66. Zhu J, Quyyumi AA, Rott D et al (2001) Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103:1071-1075 (Pubitemid 32200179)
67. Huittinen T, Leinonen M, Tenkanen L et al (2002) Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk. Arterioscler Thromb Vasc Biol 22:431-437 (Pubitemid 34218750)
68. Zhang X, He MA, Cheng L et al (2008) Joint effects of antibody to heat shock protein 60, hypertension, and diabetes on risk of coronary heart disease in Chinese. Clin Chem 54(6):1046-1052 (Pubitemid 351793412)
69. Hoppichler F, Lechleitner M, Traweger C et al (1996) Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction. Atherosclerosis 126:333-338 (Pubitemid 26336670)
70. Mukherjee M, De Benedictis C, Jewitt D, Kakkar VV (1996) Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis. Thromb Haemost 75:258-260 (Pubitemid 26081478)
71. Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS (1998) Association between antibodies to heat shock protein 65 and coronary atherosclerosis: possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 19:387-394 (Pubitemid 28120718)
72. Chan YC, Shukla N, Abdus-Samee M et al (1999) Anti-heat-shock protein 70 kDa antibodies in vascular patients. Eur J Vasc Endovasc Surg 18:381-385
73. Gromadzka G, Zielinska J, Ryglewicz D, Fiszer U, Czlonkowska A (2001) Elevated levels of anti-heat shock protein antibodies in patients with cerebral ischemia. Cerebrovasc Dis 12:235-239 (Pubitemid 32973955)
74. Frostegard J, Lemne C, Andersson B, van der Zee R, Kiessling R, de Faire U (1997) Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 29:40-44 (Pubitemid 27078338)
75. Zhang X, He M, Cheng L et al (2008) Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese. Circulation 118(25):2687-2693
76. Veres A, Füst G, Smieja M et al (2002) Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation 106(22):2775-2780 (Pubitemid 35396975)
77. Schett G, Xu Q, Amberger A et al (1995) Auto-antibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 96(6):2569-2577
78. Xu Q, Schett G, Seitz CS, Hu Y, Gupta RS, Wick G (1994) Surface staining and cytotoxic activity of heat-shock protein 60 antibody in stressed aortic endothelial cells. Circ Res 75:1078-1085 (Pubitemid 24351453)
79. Foteinos G, Afzal AR, Mandal K, Jahangiri M, Xu Q (2005) Anti-heat shock protein 60 auto-antibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation 112(8):1206-1213 (Pubitemid 41216128)
80. Yokota S, Minota S, Fujii N (2006) Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. Int Immunol 18(4):573-580
81. Dieudé M, Gillis MA, Théorêt JF et al (2009) Auto-antibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis. J Thromb Haemost 7(4):710-719
82. Kol A, Sukhova GK, Lichtman AH, Libby P (1998) Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 98:300-307 (Pubitemid 28348051)
83. Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 164:558-565
84. Asea A (2003) Chaperokine-induced signal transduction pathways. Exerc Immunol Rev 9:25-33
85. Vabulas RM, Wagner H, Schild H (2002) Heat shock proteins as ligands of Toll-like receptors. Curr Top Microbiol Immunol 270:169-184 (Pubitemid 35448160)
86. Gao B, Tsan MF (2004) Induction of cytokines by heat shock proteins and endotoxin in murine macrophages. Biochem Biophys Res Commun 317:1149-1154 (Pubitemid 38496430)
87. Tsan MF, Gao B (2004) Cytokine function of heat shock proteins. Am J Physiol Cell Physiol 286:739-744
88. Moohebati M, Bidmeshgi S, Azarpazhooh MR et al (2010) Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: a randomized, double-blind, placebo-controlled, cross-over trial. Clin Biochem (n press)
89. Yancey PG, Bortnick AE, Kellner-Weibel G, Llera-Moya M, Phillips MC, Rothblat GH (2003) Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23(5):712-719 (Pubitemid 36566157)
90. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE (2010) HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 208(1):3-9
91. Hyka N, Dayer JM, Modoux C et al (2001) Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97(8):2381-2389 (Pubitemid 32291485)
92. James RW, Deakin SP (2004) The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 37(12):1986-1994 (Pubitemid 39491318)
93. Murphy AJ, Woollard KJ, Hoang A et al (2008) High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 28(11):2071-2077
94. Abe H, Tsuboi N, Suzuki S et al (2001) Anti-apolipoprotein A-I autoantibody: characterization of monoclonal auto-antibodies from patients with systemic lupus erythematosus. J Rheumatol 28(5):990-995 (Pubitemid 32422578)
95. Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG (1998) Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7(5):355-360 (Pubitemid 28347016)
96. Vuilleumier N, Reber G, James R et al (2004) Presence of auto-antibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 23(4):353-360 (Pubitemid 39574810)
97. Vuilleumier N, Charbonney E, Fontao L et al (2008) Anti-apolipoprotein A-1 IgG are associated with high oxidised low-density lipoprotein levels in acute coronary syndrome. Clin Sci Lond 115:25-33 (Pubitemid 351930790)
98. O'Neill SG, Giles I, Lambrianides A et al (2010) Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 62(3):845-854
99. Vuilleumier N, Bratt J, Alizadeh R, Hafstrom I, Jogestrand T, Frostegard J (2010) Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scan J Rheumatol 39(6):447-453
100. Vuilleumier N, Rossier MF, Pagano S et al (2010) Anti-apolipoprotein A-1 autoantibody of IgG subtype as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 31:815-823
101. Vuilleumier N, Bas S, Pagano S et al (2010) Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients suffering from rheumatoid arthritis. Arthritis Rheum 62(9):2640-2650
102. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE (2010) HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 20:3-9
103. Batuca JR, Ames PR, Isenberg DA, Alves JD (2007) Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann NY Acad Sci 1108:137-146 (Pubitemid 47528727)
104. Clarke R, Armitage J (2002) Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials. Cardiovasc Drugs Ther 16(5):411-415 (Pubitemid 36255741)
105. Ames PR, Matsuura E, Batuca JR et al (2010) High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus 19(6):711-716
106. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM (2009) The role of dysfunctional HDL in atherosclerosis. J Lipid Res 50:S145-S149
107. Witztum JL, Horkko S (1997) The role of oxidized LDL in atherogenesis: immunological response and anti-phospholipid antibodies. Ann NY Acad Sci 811:88-96 (Pubitemid 27308318)
108. Salonen JT, Yla-Herttuala S, Yamamoto R et al (1992) Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339:883-887
109. Shoenfeld Y, Wu R, Dearing LD, Matsuura E (2004) Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 110:2552-2558 (Pubitemid 39453000)
110. Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, Yla-Herttuala S (2005) Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease. Atherosclerosis 183:157-162 (Pubitemid 41416834)
111. Luoma JS, Kareinen A, Narvanen O et al (2005) Auto-antibodies against oxidized LDL are associated with severe chest pain attacks in patients with coronary heart disease. Free Radic Biol Med 39:1660-1665 (Pubitemid 41642597)
112. Crisby M, Kublickiene K, Henareh L, Agewall S (2009) Circulating levels of auto-antibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease. Heart Vessels 24:90-95
113. Sherer Y, Pagnoux C, Chironi G et al (2008) Carotid artery intima-media thickness, heat shock proteins and oxidized LDL auto-antibodies in systemic necrotizing vasculitis. Rheumatol Int 28:1099-1103
114. Chen HW, Kuo CL, Huang CS, Kuo SJ, Liu CS (2008) Oxidized low-density lipoproteins, auto-antibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population. Cardiology 110:252-259 (Pubitemid 351919792)
115. Brandao SA, Izar MC, Fischer SM et al (2010) Early increase in auto-antibodies against human oxidized low-density lipoprotein in hypertensive patients after blood pressure control. Am J Hypertens 23:208-214
116. Wilson PW, Ben Yehuda O, McNamara J et al (2006) Auto-antibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring Study. Atherosclerosis 189:364-368 (Pubitemid 44740294)
117. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S (2003) Immunoglobulin M type of auto-antibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108:2107-2112 (Pubitemid 37337587)
118. Tsimikas S, Brilakis ES, Lennon RJ et al (2007) Relationship of IgG and IgM auto-antibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48:425-433 (Pubitemid 46220609)
119. Virella G, Lopes-Virella MF (2008) Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis 200:239-246
120. Binder CJ, Horkko S, Dewan A et al (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9:736-743 (Pubitemid 36749223)
121. Yamashita T, Freigang S, Eberle C et al (2006) Maternal immunization programs postnatal immune responses and reduces atherosclerosis in offspring. Circ Res 99:e51-e64 (Pubitemid 44498296)
122. Mayr M, Kiechl S, Tsimikas S et al (2006) Oxidized low-density lipoprotein auto-antibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol 47:2436-2443 (Pubitemid 43866376)
123. Fredrikson GN, Hedblad B, Berglund G et al (2007) Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 38:1495-1500 (Pubitemid 46684151)
124. Su J, Georgiades A, Wu R et al (2006) Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188:160-166 (Pubitemid 44160704)
125. de Faire U, Su J, Hua X et al (2010) Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun 34:73-79
126. Sjoberg BG, Su J, Dahlbom I et al (2009) Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 203:528-532
127. Fiskesund R, Stegmayr B, Hallmans G et al (2010) Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke 41:607-612
128. Gronlund H, Hallmans G, Jansson JH et al (2009) Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil 16:382-386
129. Carrero JJ, Hua X, Stenvinkel P et al (2009) Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrol Dial Transplant 24:3454-3460
130. Frostegard J, Tao W, Georgiades A et al (2007) Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr Metab Lond 20:4-7
131. Shaw PX, Horkko S, Chang MK et al (2000) Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105:1731-1740 (Pubitemid 30421754)
132. Chang MK, Binder CJ, Miller YI et al (2004) Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 200:1359-1370 (Pubitemid 39657284)
133. Horkko S, Bird DA, Miller E et al (1999) Monoclonal auto-antibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103:117-128 (Pubitemid 29031170)
134. Shaw PX, Horkko S, Tsimikas S et al (2001) Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21:1333-1339 (Pubitemid 34219841)
135. Binder CJ, Shaw PX, Chang MK et al (2005) The role of natural antibodies in atherogenesis. J Lipid Res 46:1353-1363 (Pubitemid 43109798)
136. Chou MY, Hartvigsen K, Hansen LF et al (2008) Oxidation-specific epitopes are important targets of innate immunity. J Intern Med 263:479-488 (Pubitemid 351533561)
137. Hartvigsen K, Chou MY, Hansen LF et al (2009) The role of innate immunity in atherogenesis. J Lipid Res 50:S388-S393
138. Faria-Neto JR, Chyu KY, Li X et al (2006) Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189:83-90 (Pubitemid 44468069)
139. Caligiuri G, Khallou-Laschet J, Vandaele M et al (2007) Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 50:540-546 (Pubitemid 47126777)
140. Damoiseaux J, Rijkers G, Tervaert JW (2007) Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and therefore precludes an anti-atherogenic effect. Atherosclerosis 190:10-11 (Pubitemid 44908328)
141. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF (2006) OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 47:1975-1983 (Pubitemid 44401985)
142. Hammad SM, Twal WO, Barth JL et al (2009) Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis 202:394-404
143. Piccinini AM, Midwoods KS (2010) DAMPenig inflammation by modulating TLR signalling. Mediators Inflam (in press)
144. Nussinovitch U, Shoenfeld Y (2008) Intravenous immunoglobulin - indications andmechanisms in cardiovascular diseases. Autoimmun Rev 7:445-452